OLMA Olema Pharmaceuticals, Inc. Stock Quote

OLMA [NASD]

Index	-	P/E	-	EPS (ttm)	-1.52	Insider Own	4.20%	Shs Outstand	39.61M	Perf Week	-8.38%
Market Cap	259.19M	Forward P/E	-	EPS next Y	-2.48	Insider Trans	59.24%	Shs Float	35.92M	Perf Month	-28.23%
Income	-59.60M	PEG	-	EPS next Q	-0.50	Inst Own	93.50%	Short Float	10.68%	Perf Quarter	-76.98%
Sales	-	P/S	-	EPS this Y	-455.80%	Inst Trans	2.27%	Short Ratio	4.52	Perf Half Y	-74.22%
Book/sh	7.60	P/B	0.86	EPS next Y	-41.70%	ROA	-18.30%	Target Price	46.25	Perf Year	-84.73%
Cash/sh	7.74	P/C	0.85	EPS next 5Y	-	ROE	-18.60%	52W Range	6.27 - 54.88	Perf YTD	-29.91%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-88.05%	Beta	-
Dividend %	-	Quick Ratio	34.60	Sales past 5Y	-	Gross Margin	-	52W Low	4.63%	ATR	0.71
Employees	60	Current Ratio	34.60	Sales Q/Q	-	Oper. Margin	-	RSI (14)	22.31	Volatility	7.64% 8.27%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-24.30%	Profit Margin	-	Rel Volume	0.50	Prev Close	6.69
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	849.16K	Price	6.56
Recom	1.60	SMA20	-23.55%	SMA50	-54.82%	SMA200	-73.16%	Volume	423,233	Change	-1.94%

Dec-07-21

Resumed

Cowen

Outperform

Dec-14-20

Initiated

JP Morgan

Overweight

$52

Dec-14-20

Initiated

Jefferies

Buy

$70

Dec-14-20

Initiated

Cowen

Outperform

Dec-14-20

Initiated

Canaccord Genuity

Buy

$60

Jan-04-22 07:30AM	Olema Oncology to Present at 40th Annual J.P. Morgan Healthcare Conference GlobeNewswire -5.83%
Dec-16-21 12:38PM	Tybourne Capital Management (hk) Ltd Buys Snowflake Inc, Pinduoduo Inc, KE Holdings Inc, Sells ... GuruFocus.com
Dec-01-21 04:09PM	Has Olema Stock Hit Bottom? JPMorgan Sees a Silver Lining TipRanks +8.34%
Nov-30-21 11:02AM	OLMA Stock: The Breast Cancer Therapy News That Has Olema Pharmaceuticals Plunging Today InvestorPlace -60.02%
07:00AM	Olema Oncology Announces First Clinical Data on OP-1250 in Advanced ER+ / HER2- Breast Cancer GlobeNewswire
Nov-29-21 04:27PM	Olema Oncology Issues Statement Regarding Falsified Information Circulating on Social Media GlobeNewswire
Nov-22-21 07:30AM	Olema Oncology to Present New Data on OP-1250 at 2021 San Antonio Breast Cancer Symposium GlobeNewswire -6.63%
Nov-19-21 12:00PM	33 Stocks Moving In Friday's Mid-Day Session Benzinga -8.67%
Nov-10-21 04:05PM	Olema Oncology Reports Third Quarter 2021 Financial Results and Provides Corporate Update GlobeNewswire
Nov-09-21 07:30AM	Olema Oncology to Present at Two Upcoming Investor Conferences GlobeNewswire
Oct-18-21 11:01AM	Notable Olema Pharmaceuticals Insider Trades $175K In Company Stock Benzinga -7.20%
Oct-13-21 11:43AM	Chief Business Officer Of Olema Pharmaceuticals Trades $155K In Company Stock Benzinga
Sep-30-21 05:00PM	Olema Oncology Announces Trials in Progress Poster on OP-1250 at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics GlobeNewswire
Sep-09-21 07:30AM	Olema Oncology to Present Data on OP-1250 at the 2021 JCA-AACR Precision Cancer Medicine International Conference GlobeNewswire
Aug-30-21 04:05PM	Olema Oncology to Present at Morgan Stanley 19th Annual Global Healthcare Conference GlobeNewswire
Aug-18-21 10:46AM	Companies Like Olema Pharmaceuticals (NASDAQ:OLMA) Are In A Position To Invest In Growth Simply Wall St.
Aug-10-21 04:05PM	Olema Oncology Reports Second Quarter 2021 Financial Results and Provides Corporate Update GlobeNewswire
Jul-28-21 04:05PM	Olema Oncology to Present at Canaccord Genuity 41st Annual Growth Conference GlobeNewswire
May-18-21 04:05PM	Olema Oncology to Participate at the Jefferies 2021 Virtual Healthcare Conference GlobeNewswire
May-11-21 04:05PM	Olema Oncology Reports First Quarter 2021 Financial Results and Provides Corporate Update GlobeNewswire
Apr-07-21 07:30AM	Olema Oncology to Participate in the Canaccord Genuity Horizons in Oncology Virtual Conference GlobeNewswire -6.20%
Apr-06-21 07:30AM	Olema Oncology Appoints Oncology Biotech Executive Yi Larson, MBA, to Board of Directors GlobeNewswire -8.28%
Mar-17-21 04:05PM	Olema Oncology Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Updates GlobeNewswire
Mar-10-21 04:45PM	Olema Oncology Announces Late-Breaking Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2021 GlobeNewswire +8.82%
Feb-23-21 07:00AM	Olema Oncology to Participate at Upcoming Virtual Investor Conferences GlobeNewswire -15.01%
Feb-19-21 04:59AM	We're Hopeful That Olema Pharmaceuticals (NASDAQ:OLMA) Will Use Its Cash Wisely Simply Wall St. +7.07%
Dec-31-20 03:42PM	Biotech IPO Frenzy Brings in 3 Stocks to Buy TipRanks
Dec-17-20 07:00AM	Olema Oncology to Present at 39th Annual J.P. Morgan Virtual Healthcare Conference GlobeNewswire +8.03%
Dec-07-20 07:39AM	Olema Oncology Announces Two Poster Presentations at the San Antonio Breast Cancer Symposium 2020 GlobeNewswire -8.31%
Dec-03-20 05:18PM	Kinnate Biopharma Stock Nearly Doubles in Debut. More Deals Are Coming. Barrons.com
Nov-23-20 04:01PM	Olema Oncology Announces Closing of Initial Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire +7.93%
Nov-20-20 01:33PM	Maravai LifeSciences Jumps Nearly 19% in IPO, While Sotera Pops 17% Barrons.com
Nov-19-20 06:39PM	IPOs Are Back After Election Pause. Olema Pharmaceuticals Stock Jumped 158%. Barrons.com

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Horn Kinney	CHIEF BUSINESS OFFICER	Jan 10	Option Exercise	2.06	5,251	10,838	7,709	Jan 11 08:21 PM
Horn Kinney	CHIEF BUSINESS OFFICER	Jan 10	Sale	6.85	5,251	35,969	2,458	Jan 11 08:21 PM
Horn Kinney	CHIEF BUSINESS OFFICER	Dec 10	Option Exercise	2.06	5,251	10,838	7,709	Dec 14 04:25 PM
Horn Kinney	CHIEF BUSINESS OFFICER	Dec 10	Sale	10.39	5,251	54,558	2,458	Dec 14 04:25 PM
Myles David C.	CHIEF DEVELOPMENT OFFICER	Dec 10	Sale	10.30	10,000	103,000	582,901	Dec 14 04:03 PM
BVF PARTNERS L P/IL	Director	Nov 30	Buy	9.39	739,675	6,945,770	3,755,093	Dec 02 08:45 PM
Harmon Cyrus	CHIEF TECHNOLOGY OFFICER	Nov 29	Sale	24.76	400	9,904	1,051,146	Dec 01 05:34 PM
Horn Kinney	CHIEF BUSINESS OFFICER	Nov 10	Option Exercise	15.79	27,668	436,761	29,458	Nov 12 05:15 PM
Horn Kinney	CHIEF BUSINESS OFFICER	Nov 10	Sale	26.88	27,668	743,716	1,790	Nov 12 05:15 PM
Harmon Cyrus	CHIEF TECHNOLOGY OFFICER	Oct 19	Sale	27.98	12,000	335,794	1,051,546	Oct 21 04:33 PM
Bohen Sean	PRESIDENT AND CEO	Oct 14	Option Exercise	4.82	5,000	24,120	57,514	Oct 15 06:44 PM
Bohen Sean	PRESIDENT AND CEO	Oct 14	Sale	30.47	5,000	152,363	52,514	Oct 15 06:44 PM
Horn Kinney	CHIEF BUSINESS OFFICER	Oct 11	Option Exercise	2.06	5,251	10,838	7,041	Oct 12 06:53 PM
Horn Kinney	CHIEF BUSINESS OFFICER	Oct 11	Sale	27.90	5,251	146,510	1,790	Oct 12 06:53 PM
Bohen Sean	PRESIDENT AND CEO	Sep 27	Option Exercise	4.82	1,085	5,234	53,599	Sep 29 07:56 PM
Bohen Sean	PRESIDENT AND CEO	Sep 27	Sale	30.07	1,085	32,626	52,514	Sep 29 07:56 PM
Harmon Cyrus	CHIEF TECHNOLOGY OFFICER	Sep 20	Sale	26.30	12,000	315,600	1,063,546	Sep 21 06:19 PM
Horn Kinney	CHIEF BUSINESS OFFICER	Sep 10	Option Exercise	2.06	5,251	10,838	7,041	Sep 13 08:07 PM
Horn Kinney	CHIEF BUSINESS OFFICER	Sep 10	Sale	29.38	5,251	154,274	1,790	Sep 13 08:07 PM
Bohen Sean	PRESIDENT AND CEO	Sep 08	Option Exercise	4.82	2,631	12,692	56,905	Sep 09 04:25 PM
Bohen Sean	PRESIDENT AND CEO	Sep 08	Sale	30.00	2,631	78,930	52,514	Sep 09 04:25 PM
Bohen Sean	PRESIDENT AND CEO	Sep 07	Option Exercise	4.82	413	1,992	54,687	Sep 09 04:25 PM
Bohen Sean	PRESIDENT AND CEO	Sep 07	Sale	30.08	413	12,423	54,274	Sep 09 04:25 PM
Bohen Sean	PRESIDENT AND CEO	Sep 01	Option Exercise	4.82	871	4,202	55,145	Sep 03 05:16 PM
Bohen Sean	PRESIDENT AND CEO	Sep 01	Sale	30.05	871	26,174	54,274	Sep 03 05:16 PM
Harmon Cyrus	CHIEF TECHNOLOGY OFFICER	Aug 19	Sale	24.97	12,000	299,640	1,075,546	Aug 20 09:14 PM
Horn Kinney	CHIEF BUSINESS OFFICER	Aug 10	Option Exercise	2.06	5,251	10,838	7,041	Aug 11 06:05 PM
Horn Kinney	CHIEF BUSINESS OFFICER	Aug 10	Sale	25.71	5,251	134,979	1,790	Aug 11 06:05 PM
Harmon Cyrus	CHIEF TECHNOLOGY OFFICER	Jul 20	Sale	25.63	4,123	105,672	1,087,546	Jul 21 05:29 PM
Harmon Cyrus	CHIEF TECHNOLOGY OFFICER	Jul 19	Sale	24.83	7,877	195,586	1,091,669	Jul 21 05:29 PM
Horn Kinney	CHIEF BUSINESS OFFICER	Jul 12	Option Exercise	2.06	5,251	10,838	7,041	Jul 13 06:27 PM
Horn Kinney	CHIEF BUSINESS OFFICER	Jul 12	Sale	26.51	5,251	139,191	1,790	Jul 13 06:27 PM
Harmon Cyrus	CHIEF TECHNOLOGY OFFICER	Jun 18	Sale	24.80	12,000	297,626	1,099,546	Jun 21 07:05 PM
Horn Kinney	CHIEF BUSINESS OFFICER	Jun 10	Option Exercise	2.06	5,251	10,838	7,041	Jun 11 04:30 PM
Horn Kinney	CHIEF BUSINESS OFFICER	Jun 10	Sale	29.72	5,251	156,071	1,790	Jun 11 04:30 PM
Horn Kinney	CHIEF BUSINESS OFFICER	May 18	Option Exercise	2.06	57,763	119,223	59,553	May 19 08:18 PM
Horn Kinney	CHIEF BUSINESS OFFICER	May 18	Sale	24.15	57,763	1,394,769	1,790	May 19 08:18 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience